Vancouver, British Columbia – (February 4th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide a market update report with key activities undertaken by BioMark’s team during January 2020. “BioMark is not aware of any negative news that has impacted its share price recently. We continue to execute […]
© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.